These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 628213)

  • 1. Response of lymphoid leukemia L1210 in mice to implantable sustained release cytosine arabinoside capsules.
    Fu JC; Khwaja T; Moyer DL; Cummings L; Varvan J; Elshire D
    J Surg Oncol; 1978; 10(1):1-7. PubMed ID: 628213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
    Hashida M; Kojima T; Muranishi S; Sezaki H
    Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Studies on the relationship between therapeutic schedule and antitumor effect of etoposide and cytosine arabinoside in murine L1210 leukemia].
    Ooi K; Ohkubo T; Kawasaki H; Sakurai M
    Yakugaku Zasshi; 1989 Nov; 109(11):865-8. PubMed ID: 2614669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210.
    Avery TL; Roberts D
    Eur J Cancer (1965); 1974 Jul; 10(7):425-9. PubMed ID: 4457345
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
    Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
    Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model.
    Grem JL; Plowman J; Rubinstein L; Hawkins MJ; Harrison SD
    Leuk Res; 1991; 15(4):229-36. PubMed ID: 2030604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
    Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
    Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
    Rose WC; Trader MW; Laster WR; Schabel FM
    Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
    Kline I; Woodman RJ; Gang M; Sirica A; Venditti JM; Goldin A
    Cancer Chemother Rep; 1972 Jun; 56(3):327-34. PubMed ID: 19051491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
    Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
    Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of antitumor agents administered subcutaneously to L1210 leukemic mice in silicone rubber devices.
    Neil GL; Scheidt LG; Kuentzel SL; Moxley TE
    Chemotherapy; 1973; 18(1):27-40. PubMed ID: 4681847
    [No Abstract]   [Full Text] [Related]  

  • 14. 1-beta-D-arabinofuranosylcytosine conjugates of corticosteroids as potential antitumor agents.
    Hong CI; Nechaev A; Kirisits AJ; Buchheit DJ; West CR
    Eur J Cancer Clin Oncol; 1983 Aug; 19(8):1105-12. PubMed ID: 6684555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
    Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
    Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
    Hoffman GS; Kline I; Gang M; Tyrer DD; Goldin A; Mantel N; Venditti JM
    Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613
    [No Abstract]   [Full Text] [Related]  

  • 17. A computer model for tumor growth and chemotherapy, and its application to L1210 leukemia treated with cytosine arabinoside (NSC-63878).
    Shackney SE
    Cancer Chemother Rep; 1970 Dec; 54(6):399-429. PubMed ID: 5527022
    [No Abstract]   [Full Text] [Related]  

  • 18. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L1210 cells.
    Nakayama T; Sakamoto S; Sassa S; Suzuki S; Kudo H; Nagasawa H
    Anticancer Res; 2005; 25(1A):157-60. PubMed ID: 15816533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.